Biosimilars
What This Page Covers
This page collects the 4 public records POLISCOPE has tagged with “Biosimilars”. Coverage spans bills - each decoded into plain English and linked to its primary source. It most often overlaps with Healthcare, Fda, and Drug Regulation.
Active Bills
Recent Activity
No recent activity found for this topic in the available records yet.
Browse recent local activity →Finance Signals
No finance signals found for this topic in the available records yet.
Open the Money page to search by entity, donor, or PAC.
Reported financial relationships and timing signals. This does not prove motive or influence.
Key Actors
- 01Janet Woodcockperson2 mentions
- 02Committee on Health, Education, Labor, and Pensionsorganization1 mentions
- 03Bill Cassidyperson · R · Member of Congress1 mentions
- 04Food and Drug Administrationorganization1 mentions
- 05The Pew Charitable Trustsorganization1 mentions
- 06Michael C Burgessperson1 mentions
- 07U.S. Food and Drug Administrationorganization1 mentions
- 08Subcommittee on Primary Health and Retirement Securityorganization1 mentions
- 09Association for Accessible Medicinesorganization1 mentions
- 10Public Health Service Actconcept1 mentions
Connections Preview
Lightweight relationship summary. Open the full graph for the interactive view, including 1-hop neighbours and money edges.
- Topic to billsProposed Changes to Biosimilar Drug Review Process
- Topic to peopleJanet Woodcock, Bill Cassidy, Michael C Burgess
- Topic to orgsCommittee on Health, Education, Labor, and Pensions, Food and Drug Administration, The Pew Charitable Trusts (+3 more)
Source Trail
Documents whose extracted record lists this topic. Each item opens the Bill Dossier, which includes the official source URL when available.
- Jul 21, 2026Federal BillProposed Changes to Biosimilar Drug Review Process
- Jan 1, 2018hearing transcriptCongressional Hearing on FDA Drug Approval Fees
- Jan 1, 2017hearing transcriptSenate Hearing: FDA Progress on Biosimilar Drugs
Showing 3 of 4 source records.